Cargando…

Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis

Posaconazole is a new oral triazole with broad-spectrum antifungal activity. Posaconazole has also shown a significant advantage of preventing invasive fungal infection compared to fluconazole or itraconazole in patients with prolonged neutropenia. Indeed, posaconazole has been commonly used for ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Seung Hun, Kim, Hyun Seon, Bae, Myoung Nam, Kim, Jihye, Yoo, Ji Yeon, Lee, Kwan Yong, Lee, Dong-Gun, Kim, Hee-Je
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384455/ https://www.ncbi.nlm.nih.gov/pubmed/25844263 http://dx.doi.org/10.3947/ic.2015.47.1.49

Ejemplares similares

941. Isavuconazole Prophylaxis Against Invasive Fungal Infection: A Pooled Analysis with a Comparison of Posaconazole Delayed-release Tablet Prophylaxis
por: Lee, Chaeryoung, et al.
Publicado: (2021)

Risk of recurrent stroke and antiplatelet choice in breakthrough stroke while on aspirin
por: Kim, Joon-Tae, et al.
Publicado: (2020)

Successful treatment of pulmonary mucormycosis caused by Rhizopus microsporus with posaconazole
por: Yuan, F., et al.
Publicado: (2021)

Successful treatment of cutaneous mucormycosis disseminated from pulmonary mucormycosis with liposomal amphotericin B and posaconazole
por: Ding, Xiao-Lan, et al.
Publicado: (2020)

Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents
por: Kang, Ka-Won, et al.
Publicado: (2020)

TR34/L98H Mutation in CYP51A Gene in Aspergillus fumigatus Clinical Isolates During Posaconazole Prophylaxis: First Case in Korea
por: Lee, Hyeon-Jeong, et al.
Publicado: (2018)

Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis
por: Calmettes, Claire, et al.
Publicado: (2018)

Fatal breakthrough mucormycosis in a multivisceral transplant patient receiving micafungin: Case report and literature review
por: Louis-Auguste, John R., et al.
Publicado: (2018)

Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea
por: Yang, Eunmi, et al.
Publicado: (2021)

Posaconazole Treatment in Korea: Single-Center Experience Over 5 Years
por: Lee, Hyo-Jin, et al.
Publicado: (2013)

Incidence of invasive fungal infection in acute lymphoblastic and acute myelogenous leukemia in the era of antimold prophylaxis
por: Oh, Sang-Min, et al.
Publicado: (2021)

2696. Breakthrough Toxoplasmosis While on Atovaquone Prophylaxis Following Allogeneic Hematologic Stem Cell Transplantation
por: Chueng, Teresa A, et al.
Publicado: (2019)

1469 Posaconazole salvage treatment for invasive fungal infection : a single center experience with utilization of posaconazole oral suspension or delayed-released tablet
por: Kim, Jong Hun, et al.
Publicado: (2014)

Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain
por: Cámara, Rafael, et al.
Publicado: (2017)

Fatal Pulmonary Mucormycosis Caused by Rhizopus microsporus in a Patient with Diabetes
por: Kim, Moon Jin, et al.
Publicado: (2014)

Posaconazole in the Prevention of COVID-19-associated Mucormycosis: A Concerning Contributor to the Rise in Antifungal Resistance
por: Kayarat, Bhavana, et al.
Publicado: (2021)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis
por: Leelawattanachai, Pannee, et al.
Publicado: (2019)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

A Rare Case of Fatal Endobronchial Mucormycosis Masquerading as Endobronchial Tuberculosis
por: Kim, Minjeong, et al.
Publicado: (2020)

Acute Kidney Injury Following Posaconazole for Mucormycosis: SARS-CoV-2 as a Back-Seat Driver
por: Noor, Mohammad, et al.
Publicado: (2022)

Selective Bowel Decontamination for the Prevention of Infection in Acute Myelogenous Leukemia: A Prospective Randomized Trial
por: Lee, Dong Gun, et al.
Publicado: (2002)

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia
por: Tu, Songji, et al.
Publicado: (2023)

Posaconazole for lobomycosis
por: Pasqualotto, Alessandro C., et al.
Publicado: (2021)

Intraparenchymal Hemorrhage: A Fatal Presentation of Undiagnosed Acute Myelogenous Leukemia
por: Hamadi, Rachelle, et al.
Publicado: (2022)

2119. Matched-Paired Analysis of Patients Treated for Invasive Mucormycosis—Standard Treatment vs. Posaconazole New Formulations (MoveOn)
por: Salmanton-Garcia, Jon, et al.
Publicado: (2019)

Oral posaconazole and bronchoscopy as a treatment for pulmonary mucormycosis in pediatric acute lymphoblastic leukemia patient: A case report
por: Liang, Yan, et al.
Publicado: (2021)

Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series
por: Soman, Rajeev, et al.
Publicado: (2022)

The use of posaconazole delayed-release tablets in the successful treatment of suspected mucormycosis in a bottlenose dolphin (Tursiops truncatus) calf
por: Marques, Gonçalo N., et al.
Publicado: (2021)

Mucormycosis in a Severe Trauma Patient Treated with a Combination of Systemic Posaconazole and Topical Amphotericin B—Case Report
por: Keller, Filip, et al.
Publicado: (2023)

Optimization of Oral Posaconazole Step Down Therapy in Management of Rhino-Orbital-Cerebral Mucormycosis (ROCM): Outcome of an Institutional Protocol
por: Mukherjee, Monoj, et al.
Publicado: (2023)

2731. Posa-bly the Better Option? Comparison of Posaconazole vs. Itraconazole for Antifungal Prophylaxis After Heart Transplantation
por: Drucker, Darra, et al.
Publicado: (2023)

The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study
por: Özkocaman, Vildan, et al.
Publicado: (2018)

Economic analysis of oral posaconazole prophylaxis in acute myeloid leukemia during remission induction in Turkey
por: Umit, Elif Gulsum, et al.
Publicado: (2020)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies
por: Suh, Hyeon Jeong, et al.
Publicado: (2017)

Lichtheimia ramosa: A Fatal Case of Mucormycosis
por: Mouronte-Roibás, Cecilia, et al.
Publicado: (2016)

Fatal disseminated mucormycosis associated with COVID‐19
por: Horiguchi, Tomoya, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Posaconazole: an Update
por: Dekkers, Bart G. J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e4l7e32i3mro3l19v5hsjffdot